The synergism between atrial fibrillation and heart failure

Melissa Byrne1, David M Kaye, John Power

  • 1Baker Heart Research Institute, Melbourne, Victoria,Australia.

Insights

Atrial fibrillation (AF) worsens heart failure (HF) by depressing cardiac function and activating neurohormones. Reducing mitral regurgitation (MR) in HF patients may decrease AF susceptibility.

Area of Science:

  • Cardiology
  • Cardiac Electrophysiology
  • Heart Failure Research

Background:

  • Atrial fibrillation (AF) is a common comorbidity in heart failure (HF) patients, accelerating HF progression.
  • The interaction between AF and HF is bidirectional, with each condition promoting the other.
  • Mechanisms underlying the synergistic relationship between AF and HF remain unclear.

Purpose of the Study:

  • To investigate the mechanisms of the synergistic relationship between AF and HF in an ovine model.
  • To identify how AF affects cardiac function and neurohormonal activation in the context of HF.
  • To explore how HF influences AF susceptibility, focusing on functional mitral regurgitation (MR).

Main Methods:

  • Pacing-induced congestive heart failure (HF) was established in adult sheep.
  • Atrial fibrillation (AF) was induced in HF animals using programmed extrastimuli.
  • Left ventricular hemodynamics and cardiac neurohormonal activation were assessed via coronary sinus sampling during rest and exercise.

Main Results:

  • Animals with both HF and AF (HF + AF) showed increased coronary sinus norepinephrine, endothelin-1, and brain natriuretic peptide levels.
  • HF + AF animals exhibited reduced left ventricular end-diastolic pressure and maximal rate of pressure rise compared to HF alone.
  • Cardioversion in HF + AF animals improved contractility and reduced neurohormonal markers.
  • Reducing functional mitral regurgitation (MR) in HF animals significantly decreased AF inducibility.

Conclusions:

  • AF induction significantly impairs left ventricular function and activates myocardial neurohormones in HF.
  • Functional MR in HF increases susceptibility to AF.
  • Percutaneous mitral annular reduction, by addressing MR, may attenuate AF inducibility in HF patients.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...